BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tabirafusp tedromer readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tabirafusp tedromer\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07734844-5078@assetmemo.bio
DTSTAMP:20261121T005821Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Tabirafusp tedromer: Phase 3 readout est. (NCT07734844)
DESCRIPTION:Tabirafusp tedromer\, phase 3\, Diabetic Macular Edema.\nStudy:
  A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compar
 ed to Aflibercept in Participants With DME - ALTO\nEstimated primary compl
 etion: 31 August 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/tabirafusp-tedromer#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07734844
URL:https://assetmemo.bio/drug/tabirafusp-tedromer#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
